NCL

Across TCGA pan-cancer cohorts, NCL RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of NCL’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where NCL RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NCL is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

STAD, COAD, and HNSC are the cancer types where NCL tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NCL RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	III,IV	+1.521	<.001	11	view →
COAD	All	III,IV	+1.056	<.001	11	view →
HNSC	Male	All	+0.903	<.001	11	view →
LIHC	Male	II,III,IV	+1.104	<.001	9	view →
LUSC	All	III,IV	+1.356	<.001	8	view →
LUAD	Male	All	+0.570	<.001	8	view →
KIRC	All	All	+0.253	<.001	6	view →
BRCA	All	All	+0.234	<.001	6	view →
CHOL	All	II,III,IV	+2.619	<.001	5	view →
KICH	Female	All	−1.078	<.001	5	view →
READ	All	III,IV	+1.885	.002	4	view →
ESCA	All	All	+0.993	.010	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

NCL–STAD

Open the STAD breakdown →